Dermatology Times, October 2024 (Vol. 45. No. 10)

Learn more about the in-depth topics covered in the October 2024 print issue of Dermatology Times.

Understanding the varying tax aspects of S corporations and C corporations is an important first step in determining which structure will work best for your practice.

Lal emphasizes the dual approach of combining medical and cosmetic dermatology to effectively address skin issues like hyperpigmentation.

Song stressed the need for careful therapy selection in patients with comorbid conditions to avoid exacerbating health issues.

Historically, research and clinical practice often have overlooked the distinct manifestations and treatment needs of patients with skin of color who have psoriasis.

In this month's Cosmetic Conundrums column, explore 4 eyelash growth scenarios.

Along with this new transparency regarding treatments, patients are empowered to embrace more comprehensive beauty ideals.

In October's cover feature, Nicole A. Negbenebor, MD, FAAD, discusses the benefits of intralesional 5-fluorouracil injection for older patients with squamous cell carcinoma who may elect to delay therapy or are not ideal candidates for surgery.

Experts shared pearls for acne and rosacea care at Maui Derm NP+PA Fall.

Christopher Bunick, MD, PhD, and Raj Chovatiya, MD, PhD, discuss results of an open-label phase 3b/4 study for atopic dermatitis.

Dermatology offers the power of choice, and it can be exactly what you make of it, writes our Fall Editor in Chief Raj Chovatiya, MD, PhD.

Join Dermatology Times in honoring World Mental Health Day on Oct 10, 2024.

Learn more about the latest in dermatology from Sheila Fallon Friedlander, MD; Melodie Young, MSN, ANP-c; Raj Chovatiya, MD, PhD, MSCI; Julie Harper, MD; and Matthew Zirwas, MD.

At Maui Derm NP+PA Fall 2024, Ted Rosen, MD, and George Hightower, MD, PhD, review the landscape of infectious diseases that can have dermatologic involvement, including viral, bacterial, fungal, and parasitic illnesses.

The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.